Close
Biotechgate
| |

Home Page

Action required: Please refresh your browser

We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.

More details about this topic are available here »

Axovant to Present at First Annual Roivant Pipeline Day
By: Nasdaq / GlobeNewswire - 18 Jun 2018Back to overview list

BASEL, Switzerland, June 18, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON) today announced that Pavan Cheruvu, M.D., chief executive officer, will present a corporate overview at the first annual Roivant Pipeline Day on July 10, 2018 at 4:30 p.m. ET.

A live webcast will be available in the Investors section of Axovant's website at www.axovant.com. A replay will be available for 30 days following the conference.

About Roivant Pipeline Day

Roivant Pipeline Day will be held on Tuesday, July 10, 2018 in New York City. The event will feature presentations, fireside chats, and Q&A sessions from executives across the Roivant family of companies. The event is scheduled to begin at 2:00 p.m. ET and will continue until approximately 5:30 p.m. ET. Due to limited capacity, attendance is by invitation only but a live webcast will be available to interested parties. To request access to the webcast or to learn more about the event, please email pipelineday@roivant.com.

About Axovant Sciences

Axovant is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics in the fields of neurology and psychiatry. We are developing a pipeline of clinical and nonclinical product candidates that focuses on the various aspects of debilitating neurodegenerative diseases such as Parkinson’s disease, Alzheimer's disease, Lewy body dementia, and other indications in the fields of neurology and psychiatry. Our goal is to be the leading biopharmaceutical company focused on the fields of neurology and psychiatry.

For more information, visit www.axovant.com.

Contacts:

Investors

Tricia Truehart
(631) 892-7014
investors@axovant.com

Media

Paul Davis
(646) 495-5310
media@axovant.com

SOURCE Axovant Sciences

 

Related companies:Axovant Gene Therapies | Axovant Gene Therapies
Copyright 2018 Nasdaq / GlobeNewswire Back to overview list
to the top ↑